|
US2016095908A1
|
|
Botulinum Toxin for Primary Disorders of Mood and Affect using Neurotransmitter CNS imaging Studies
|
|
US2015258183A1
|
|
Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
|
|
US2006182767A1
|
|
High-potency botulinum toxin formulations
|
|
WO2005067967A1
|
|
Methods of using botulinum toxin for the treatment of hypervolemic lip deformity (lip ectropion)
|
|
EP1905448A2
|
|
Selection of patients with increased responsiveness to botulinum toxin
|
|
CA2518155A1
|
|
Treatment of chronic chalazion and hordeolum with botulinum toxin
|
|
AU2004216904A1
|
|
Treatment of sinusitis related chronic facial pain and headache with botulinum toxin
|
|
WO2004078200A1
|
|
Selection of patients with increased responsiveness to botulinum toxin
|
|
MXPA05006690A
|
|
Pharmaceutical botulinum toxin compositions.
|
|
US7459164B2
|
|
Composition for therapeutic and cosmetic botulinum toxin
|
|
EP1334729A1
|
|
Therapeutic use of non-neurotoxic clostridium botulinum toxin type C2
|
|
US6429189B1
|
|
Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases
|
|
US7537773B1
|
|
Chemodenervating pharmaceutical as anti-inflammatory agent
|
